National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

 

NCPE Assessment Process Complete
Rapid review commissioned 03/10/2018
Rapid review completed 15/11/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended